REVIEW article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1629577
TNF Superfamily Molecules in Atherosclerosis: Mechanistic Insights and Therapeutic Translation
Provisionally accepted
- 1Bethune First Clinical School of Medicine, The First Hospital of Jilin University, Changchun, China
- 2Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Atherosclerosis (AS) is the core pathological mechanism underlying myocardial infarction and stroke, which are among the leading causes of death worldwide. The landmark CANTOS trial provided robust validation of anti-inflammatory immunotherapy as a viable approach for AS treatment, thereby underscoring the critical role of inflammatory-immune dysregulation in the pathogenesis of AS. Members of the tumor necrosis factor superfamily (TNFSF), acting as key co-stimulatory immune checkpoints, exhibit spatiotemporally precise regulatory effects on the progression of AS.They achieve this by modulating lipid metabolic disorders, dynamic plaque evolution, and thrombotic complications. Numerous TNFSF-targeted immunotherapeutics have been introduced into clinical practice, showing significant efficacy in oncology and autoimmune diseases. This offers novel insights into the dissection of the TNFSF immune network and the development of therapeutic targets. This review aims to systematically analyze the mechanistic roles of TNFSF co-stimulatory molecules in AS pathology. It also synthesizes current clinical trial outcomes and approved drug profiles, emphasizing their great potential as biomarkers and therapeutic targets for AS and related cardiovascular diseases. Furthermore, it outlines future directions in drug discovery, highlighting that targeting TNFSF downstream signaling pathways and cell type-specific therapies may emerge as groundbreaking strategies for effective AS management.
Keywords: Atherosclerosis, TNF superfamily, co-stimulatory molecules, immune checkpoints, Inflammation
Received: 16 May 2025; Accepted: 01 Aug 2025.
Copyright: © 2025 Luo, Zhang, Xie, Wu, Wang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Di Ma, Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.